ZyVersa Therapeutics ZVSA

ZyVersa Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company leverages proprietary technologies discovered by research scientists at the University of Miami, Miller School of Medicine to advance its product candidates through preclinical and clinical development. Its mission centers on optimizing health outcomes and improving patients’ quality of life through innovative therapeutic solutions.

ZyVersa Therapeutics, Inc. generates revenue primarily through the advancement and potential commercialization of its two proprietary drug development platforms. The company does not currently have any marketed products or generate revenue from product sales, as its candidates remain in preclinical or clinical development stages. Revenue generation is anticipated upon successful regulatory approval and subsequent sales of its drug candidates, supported by strategic alliances, collaborations, and potential licensing agreements with larger pharmaceutical entities to share development risks and expand commercial reach.

The company operates through the following segments: Cholesterol Efflux Mediator TM VAR 200 Platform and Inflammasome ASC Inhibitor IC 100 Platform.

• Cholesterol Efflux Mediator TM VAR 200 Platform: This segment focuses on the development of VAR 200, an injectable drug in clinical development for the treatment of chronic glomerular diseases. VAR 200, also known as 2-hydroxypropyl-beta-cyclodextrin (2HPβCD), is designed to mediate the removal of excess cholesterol and lipids from renal glomeruli to preserve kidney structure and function and reduce proteinuria. The lead indication for this platform is focal segmental glomerulosclerosis (FSGS), with additional potential indications in Alport syndrome and diabetic kidney disease, based on preclinical proof-of-concept data in animal models representing these conditions.
• Inflammasome ASC Inhibitor IC 100 Platform: This segment involves the development of IC 100, a humanized monoclonal antibody targeting the adaptor protein ASC of inflammasomes to inhibit inflammatory cascade initiation and perpetuation. IC 100 is currently in preclinical development for the treatment of chronic inflammatory diseases, with a lead indication in cardiometabolic conditions associated with obesity. The platform aims to address multiple inflammatory conditions by disrupting ASC Speck formation, both intracellularly and extracellularly, thereby blocking the perpetuation of inflammation across various disease states.

ZyVersa Therapeutics, Inc. occupies a niche position within the biopharmaceutical industry as a developer of first-in-class mechanisms targeting cholesterol efflux in renal diseases and inflammasome ASC in inflammatory conditions. The company differentiates itself through its proprietary VAR 200 and IC 100 platforms, which are licensed from university-derived entities and supported by preclinical evidence showing potential to modulate disease pathways not adequately addressed by existing therapies. Competitors in the renal space include other firms developing drugs for FSGS targeting inflammation, hypertension, and fibrosis, while in the inflammatory arena, several companies are advancing NLRP3-focused inflammasome inhibitors, though ZyVersa believes its ASC-targeting approach may offer broader inhibitory potential across multiple inflammasome types.

ZyVersa Therapeutics, Inc. serves patients suffering from chronic renal and inflammatory diseases with significant unmet medical needs. The company’s therapeutic focus includes individuals diagnosed with focal segmental glomerulosclerosis, Alport syndrome, diabetic kidney disease, and those at risk for cardiometabolic conditions due to obesity. While specific customer names such as hospitals or clinics are not disclosed in the filing, the intended end-users of its product candidates are patients receiving care through healthcare systems specializing in nephrology, cardiology, and metabolic disorders, particularly in the United States where the company seeks initial regulatory approval and commercialization.